{"schema_version":"1.0","type":"article","title":"禮來 38 億美元買三家疫苗公司：減肥藥巨頭，為什麼突然回頭買「預防醫學」？","url":"https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine.md","lang":"zh-Hant","date":"2026-06-16","publish_at":"2026-06-16T11:00:00+08:00","updated_at":"2026-06-16","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","GLP-1","疫苗","感染症","BD","臨床數據","生技投資","製藥巨頭"],"summary":"市場現在最熟悉的禮來，是 Mounjaro、Zepbound 背後那個 GLP-1 巨頭。2026 年第一季，禮來營收達到 198 億美元，年增 56%，主要動能還是來自 Mounjaro 與 Zepbound 的放量。簡單說，禮來現在手上最強的現金流，是減重與糖尿病藥物。","key_points":[],"facts":[],"sections":["01｜禮來買 Curevo：不是挑戰 Shingrix，而是挑戰疫苗接種率","02｜買 LimmaTech：抗生素失靈後，疫苗變成下一道防線","03｜買 Vaccine Company：EBV 疫苗背後，是神經疾病與癌症風險","04｜這不是 mRNA 熱潮，而是疫苗投資邏輯正在換檔","05｜GLP-1 現金流，正在變成禮來的併購燃料","06｜台灣可以看誰？不要只看疫苗題材，要看平台能力","07｜疫苗股最怕的不是沒題材，而是題材沒有續航力","結語｜禮來不是回頭買舊產業，而是在買下一代疾病預防入口"],"references":[{"title":"Eli Lilly","source":"Lilly announces three acquisitions to build infectious disease portfolio:","date":"","url":"https://investor.lilly.com/news-releases/news-release-details/lilly-announces-three-acquisitions-build-infectious-disease"},{"title":"Eli Lilly","source":"Q1 2026 Financial Results:","date":"","url":"https://lilly.gcs-web.com/news-releases/news-release-details/lilly-reports-first-quarter-2026-financial-results-raises-full"},{"title":"HHS","source":"HHS Winds Down mRNA Vaccine Development Under BARDA:","date":"","url":"https://www.hhs.gov/press-room/hhs-winds-down-mrna-development-under-barda.html"},{"title":"JAMA","source":"HHS Ends mRNA Vaccine Development:","date":"","url":"https://jamanetwork.com/journals/jama/fullarticle/2838469"}],"images":[{"alt":"Facebook 原圖：禮來 38 億美元買三家疫苗公司：減肥藥巨頭，為什麼突然回頭買「預防醫學」？（圖 1）","url":"https://drugnews.com.tw/assets/articles/lilly-vaccine-acquisitions-prevention-medicine/facebook-01.jpg"},{"alt":"Facebook 原圖：禮來 38 億美元買三家疫苗公司：減肥藥巨頭，為什麼突然回頭買「預防醫學」？（圖 2）","url":"https://drugnews.com.tw/assets/articles/lilly-vaccine-acquisitions-prevention-medicine/facebook-02.jpg"},{"alt":"Facebook 原圖：禮來 38 億美元買三家疫苗公司：減肥藥巨頭，為什麼突然回頭買「預防醫學」？（圖 3）","url":"https://drugnews.com.tw/assets/articles/lilly-vaccine-acquisitions-prevention-medicine/facebook-03.jpg"}],"cover_image":"https://drugnews.com.tw/assets/articles/lilly-vaccine-acquisitions-prevention-medicine/cover-generated.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-16）。禮來 38 億美元買三家疫苗公司：減肥藥巨頭，為什麼突然回頭買「預防醫學」？。https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-06-16-lilly-vaccine-acquisitions-prevention-medicine-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}